Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Kronox Lab Sciences Ltd.

Symbol

Equity

NSE,BSE

Min. Investment

1,29,000.00

Open a free Demat account and invest in IPOs easily.

Download Orca

Google PlayApp Store

To access realtime data for GP Eco Solutions India Ltd. and use advance features for Applying IPO. Register or Login to Orca.

IPO Details

Bidding Dates

03 Jun 24 - 05 Jun 24

Price Range ₹

129 - 136

Total Equity

91.11Cr

Lot Size

110

Exchange Status

NSE,BSE

IPO Doc

Subscription Rate

Non-Institutional Investor

55.72×

Qualified Institutional Buyers

89.03×

Employees

0.00×

Retail Investors

55.72×

Total subscription Rate

118.22×

IPO Timeline

Offer start

03 Jun 2024

Offer end

05 Jun 2024

Allotment

06 Jun 2024

Refund initiation

07 Jun 2024

Demat transfer

07 Jun 2024

Listing

10 Jun 2024

About Company

Incorporated in 2008, Kronox Lab Sciences Limited manufactures high-purity specialty fine chemicals for diverse end-user industries. These chemicals are used in various applications, including manufacturing APIs, pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products. The company offers a wide range of over 185 products, including phosphates, sulfates, acetates, chlorides, citrates, nitrates, nitrites, carbonates, EDTA derivatives, hydroxides, succinates, gluconates, and others. These products are supplied to customers in India and over 20 countries worldwide, including the United States, Argentina, Mexico, Australia, Egypt, Spain, Turkey, the United Kingdom, Belgium, the United Arab Emirates, and China. Kronox Lab Sciences operates three manufacturing facilities in Vadodara, Gujarat, near the seaports of Mundra, Kandla, Hazira, and Nhava Sheva. Covering 17,454 sq. m., these facilities have an installed capacity of 7,242 TPA as of December 31, 2023. Units I and II hold FSSC 22000 (Version 5), ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certifications, with some products from Unit I also certified as Kosher, Halal, GMP, and GLP. As of December 31, 2023, the company is conducting research and development on 122 products. Over the past three years, Kronox Lab Sciences has served over 592 customers, with 141 placing repeat orders. The company employs 212 people at various levels as of December 31, 2023.

Year Founded

18-11-2008

Promotor Details

Jogindersingh Jaswal

Promoter Holdings Details

ParticularPre-IPOPost-IPO
Percentage1000
Share Capital371040000

Offer to Public

66,99,000.00 Cr

Project Details

  • Funding working capital requirements of our Company - 304cr

Objectives

  • (i) carry out the Offer for Sale of up to 96,00,000 Equity Shares* aggregating up to ? [?] million by the Promoter Selling Shareholders
  • (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges.

Highlights

  • Kronox Lab Sciences is a debt-free company, which indicates strong financial health and reduces financial risk for investors.
  • The company manufactures over 185 products across various chemical families, catering to a wide range of industries including pharmaceuticals, scientific research, nutraceuticals, biotech, agrochemicals, personal care, metallurgy, and animal health.
  • The company's products are supplied to customers in India and over 20 countries worldwide, which helps mitigate country-specific risks and provides a diversified revenue base.
  • The company has shown consistent growth in total income and profit after tax (PAT) over the past three financial years. Total income increased from ₹62.46 crore in FY21 to ₹95.58 crore in FY23, while PAT rose from ₹9.74 crore to ₹16.83 crore in the same period.
  • With over a decade of operations, the company has a proven track record that allows investors to study its past performance and estimate its future prospects.

Challenges

  • A significant portion of the company’s revenue comes from its top 20 products, contributing around 60-70% of the total revenue in recent years. This high concentration risk could affect the company if demand for these products declines.
  • The top 10 customers contribute a substantial portion of revenue, ranging from 45% to 56% in recent years. Loss of any key customer could significantly impact the company’s revenue.
  • Most sales are to the pharmaceutical and scientific research industries. Any changes in these industries' demand or processes could lead to a loss of revenue.
  • The company supplies products in limited quantities for specific applications. A reduction in demand for these products could result in a significant business loss.
  • This IPO is an offer-for-sale, meaning the company will not receive any proceeds from it. The funds raised will go to existing shareholders selling their shares, which does not directly benefit the company’s growth or expansion plans.

Financials

YearsTotal AssetsShare CapitalProfit After TaxConsolidated Net ProfitAdjusted EPS
2023538.31371.04136.27136.273.4903
2022564.602.4197.3097.302.4922
2021374.092.4197.3097.302.4922
Enrich money logo